Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

机译：达比加群酯在美国房颤患者中的早期采用及其剂量：来自结果更好的房颤知情治疗注册的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundDabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown.

机译：背景达比加群（Dabigatran）是一种新型口服抗凝剂，已被批准用于房颤的血栓预防。这种新代理在社区实践中的采用方式尚不明确。

著录项

期刊名称 Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
作者
Benjamin A. Steinberg; DaJuanicia N. Holmes; Jonathan P. Piccini; Jack Ansell; Paul Chang; Gregg C. Fonarow; Bernard Gersh; Kenneth W. Mahaffey; Peter R. Kowey; Michael D. Ezekowitz; Daniel E. Singer; Laine Thomas; Eric D. Peterson; Elaine M. Hylek;
展开▼
作者单位

展开▼
年(卷),期 2013(2),6
年度 2013
页码 e000535
总页数 12
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
anticoagulant atrial fibrillation dabigatran dosing pharmacoepidemiology;

机译：抗凝剂;心房颤动;达比加群;给药;药物流行病学;

相似文献

外文文献
中文文献
专利

1. Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [J] . Benjamin A. Steinberg, Bernard Gersh, DaJuanicia N. Holmes, Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease . 2013,第2期

机译：达比加群酯在美国房颤患者中的早期采用及其剂量：来自结果更好的房颤知情治疗注册的结果
2. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry [J] . Jackson Larry R. II, Kim Sunghee, Shrader Peter, Journal of thrombosis and thrombolysis . 2018,第4期

机译：达比加兰的早期治疗持久性与心房颤动的患者对华法林治疗：结果注册表的结果，用于更好地了解心房颤动（轨道-AF）登记处
3. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT-AF) registry [J] . SteinbergB.A., KimS., PicciniJ.P., Circulation: An Official Journal of the American Heart Association . 2013,第7期

机译：心房颤动患者使用阿司匹林与口服抗凝剂同时使用的风险及其相关信息，可从结果注册表中了解如何更好地治疗房颤（ORBIT-AF）注册表
4. Refined Electrical Cardioversion Outcome Prediction with Bipolar Surface Standard Leads for Patients in Persistent Atrial Fibrillation [C] . Eva M. Cirugeda, Sofía Calero, Aurelio Quesada, E-Health and Bioengineering Conference . 2020

机译：对持续性心房颤动患者的双极表面标准铅的精细电气心换综合评估预测
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Clinical Characteristics Oral Anticoagulation Patterns and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry [O] . Emily C. OBrien, Sunghee Kim, Laine Thomas, 2016

机译：房颤的医疗补助患者的临床特征口服抗凝模式和结果：从结果登记处获得的见解可以更好地进行房颤知情治疗（ORBIT‐AF I）登记处
7. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry [O] . Larry R. Jackson, Sunghee Kim, Peter Shrader, 2018

机译：达比胍类对心房颤动患者的达比肽与华法林治疗的早期治疗持久性：结果注册表的更好地了解心房颤动（轨道-AF）登记处

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

摘要

著录项

相似文献

相关主题

期刊订阅